Mineralocorticoid Receptor Antagonist Pre-Adrenalectomy in Primary Aldosteronism

Применение антагонистов минералокортикоидных рецепторов до адреналэктомии при первичном альдостеронизме
Felicia Alexandra Hanzu, Monica Sala, Jessica Goi, Miguel Paja, Alicia Rizo Gellida, Marga González-Boillos, Patricia Martín Rojas‐Marcos, Laura Caja Guayerbas, Ana María García Cano, Jorge Gabriel Ruiz-Sánchez, Almudena Vicente, Emilia Gómez Hoyos, Rebeca Barahona San Millan, María José Picón César, Patricia Díaz Guardiola, Carolina María Perdomo, Laura Manjón, Ángel Rebollo Román, Cristina Robles Lázaro, José María Recio-Córdova, María Calatayud, Noemi Jiménez López, Miguel Antonio Sampedro Núñez, Elena Mena Ribas, Alicia Sanmartín Sánchez, César Gonzalvo Díaz, Cristina Lamas, Joaquín Serrano, Theodora Michalopoulou, Susana Tenés Rodrigo, Eider Pascual Corrales, Fernando Jaén Águila, Núria Muñoz Rivas, Eva María Moya Mateo, Sonsoles Gutiérrez-Medina, Paola Andrea Parra Ramírez, Marta Araujo Castro, Marga González Boillos, Joaquín Serrano, Miguel Paja Fano, Mònica Recasens, José María Recio‐Córdova
2025-10-03

Mineralocorticoid Receptor Antagonist (MRA)Primary Aldosteronism (PA)postoperative hyperkalemia riskpre-adrenalectomypreoperative MRA therapy
CONTEXT: Perioperative use of mineralocorticoid receptor antagonists (MRA) in patients with unilateral primary aldosteronism (PA) awaiting surgery is not well standardized. OBJECTIVE: The aim of this study was to compare the risk of postoperative complications and surgical outcomes between PA patients treated with MRA prior to adrenalectomy and those not pretreated. METHODS: Adrenalectomized patients for unilateral PA from the SPAIN-ALDO registry, with clinical, hormonal, and treatment information before and after adrenalectomy, were analyzed. RESULTS: A total of 355 surgically treated patients were included; 76.9% (n = 273) received presurgical treatment with MRA (spironolactone [64.5%], eplerenone [35.5%]). Adrenalectomy was guided by lateralization at adrenal venous sampling in 33.5% of the overall cohort, and by imaging in all the other cases. Patients pretreated with MRA had longer duration of hypertension, higher prevalence of hypokalemia, and greater aldosterone concentrations than those not pretreated (n = 82). No differences in the rate of postsurgical hyperkalemia, hypoaldosteronism, renal function impairment, blood pressure changes, and biochemical outcomes were detected between groups in the immediate (≤30 days) and short-term (≤90 days) follow-up evaluations after surgery. At long-term follow-up (≥6 months), patients pretreated with MRA exhibited better postsurgical biochemical outcomes (81.7% had complete biochemical response vs 57.1% of non-pretreated patients; P = .004). In the multivariable analysis, the use of MRA prior to adrenalectomy was independently associated with a successful postsurgical biochemical response. CONCLUSION: Preoperative MRA therapy can be safely introduced to control blood pressure and potassium levels in patients with PA awaiting surgery, without increasing the risk of postoperative hyperkalemia, hypoaldosteronism, renal impairment, or hypotension.
1
Preoperative MRA therapy does not increase the risk of postoperative hyperkalemia in PA patients.
2
Preoperative MRA therapy does not increase the risk of postoperative hypoaldosteronism in PA patients.
3
Preoperative MRA therapy does not increase the risk of postoperative hypotension in PA patients.
4
Preoperative MRA therapy does not increase the risk of postoperative renal impairment in PA patients.
5
Preoperative MRA therapy safely controls potassium levels in PA patients awaiting adrenalectomy.
6
Preoperative mineralocorticoid receptor antagonist (MRA) therapy safely controls blood pressure in primary aldosteronism (PA) patients awaiting adrenalectomy.

Preoperative mineralocorticoid receptor antagonist (MRA) therapy in patients with primary aldosteronism awaiting adrenalectomy

Safety and effectiveness of pre-adrenalectomy MRA therapy for controlling blood pressure and potassium levels and its impact on postoperative risks (hyperkalemia, hypoaldosteronism), renal function, and hypotension

Publication Details
Publication Date
2025-10-03
Journal
Publisher
ISSN
Cited by
8
Access Type
Author Information
Authors
Felicia Alexandra Hanzu
Monica Sala
Jessica Goi
Miguel Paja
Alicia Rizo Gellida
Marga González-Boillos
Patricia Martín Rojas‐Marcos
Laura Caja Guayerbas
Ana María García Cano
Jorge Gabriel Ruiz-Sánchez
Almudena Vicente
Emilia Gómez Hoyos
Rebeca Barahona San Millan
María José Picón César
Patricia Díaz Guardiola
Carolina María Perdomo
Laura Manjón
Ángel Rebollo Román
Cristina Robles Lázaro
José María Recio-Córdova
María Calatayud
Noemi Jiménez López
Miguel Antonio Sampedro Núñez
Elena Mena Ribas
Alicia Sanmartín Sánchez
César Gonzalvo Díaz
Cristina Lamas
Joaquín Serrano
Theodora Michalopoulou
Susana Tenés Rodrigo
Eider Pascual Corrales
Fernando Jaén Águila
Núria Muñoz Rivas
Eva María Moya Mateo
Sonsoles Gutiérrez-Medina
Paola Andrea Parra Ramírez
Marta Araujo Castro
Marga González Boillos
Joaquín Serrano
Miguel Paja Fano
Mònica Recasens
José María Recio‐Córdova
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%